REFERENCIAS

1 NCI website (http://www.nci.nih.gov)
2 Ferlay J et al, editors. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No.5. Version 2.0. IARC Press, 2004. Lyon, France.
3 Ferlay J et al, editors. Globocan 2000: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No.5. Version 1.0. IARC Press, 2001. Lyon, France.
4 Barrasso R, Guillemotonia A. Cervix and vagina: Diagnosis. In: Gross, Barrasso Eds. Human papillomavirus infection: A clinical atlas. Ullstein Mosby, 1997. p147-274.
5 Walboomers JMM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
6 Munoz N. Human papillomavirus and cancer: The epidemiological evidence. J Clin Virol 2000;19:1-5.
7 Pagliusi SR and Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-578.
8 Wieland U, Pfister H. Papillomaviruses in human pathology: Epidemiology, pathogenesis and oncogenic role. In: Gross, Barrasso Eds. Human Papilloma Virus Infection: A clinical atlas. Ullstein Mosby; 1997. p1-18.
9 IARC Handbooks of Cancer Prevention. IARC Press; 2005. Chapter 4: Efficacy of screening. p163-199.
10 Bosch FX and de Sanjosé S. Chapter 1: Human papillomavirus and cervical cancer - Burden and Assessment of causality. J Natl Cancer Inst Monogr 2003;31:3-13.
11 Jacobs MV, Walboomers JMM, Snijders PJF et al. Distribution of 37 mucosotrophic HPV types in women with cytologicaclly normal cervical smears: The age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221-227.
12 Schiffman M and Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003;31:14-19.
13 Sherman ME, Lorincz AT, Scott DR et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52
14 Ferlay et al, editors. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. Version 2.0. IARC Cancer Base No.5. IARC Press, Lyon, France, 2003.
15 Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
16 Koutsky LA, Galloway DA and Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988;10:122-163
17 Syrjänen S. Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 2005;32(Suppl 1): S59-66.
18 PHLS CDR Weekly. 2001;11(35).
19 Winer RL, Lee S-K, Hughes JP et al. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-226.
20 Sonnex C, Strauss S and Gray JJ. Detection of human papillomavirus DNA on the fingers of patients with genital warts. Sex Transm Inf 1999;75:317-319.
21 Herrero R, Castellsague X, Pawlita M et al. Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicentre study. J Natl Cancer Inst 2003;95:1772-1783.
22 Agence Nationale d’Accréditation et d’Évaluation en Santé. Clinical practice guidelines: Management of a patient with an abnormal cervical smear. 2002 update.
23 Goldie SJ, Kohli M, Grima D et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-615.
24 Beutner KR and Wiley DJ. Recurrent external genital warts: A literature review. Papillomavirus Rep 1997;8:69-74.
25 McMillan A. The management of difficult anogenital warts. Sex Transm Inf 1999;75:192-194.
26 Kyrgiou M, Koliopoulos G, Martin-Hirsch P et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. Lancet 2006;367:489-498.
27 McDonald TW, Neutens JJ, Fischer LM et al. Impact of cervical intraepithelial neoplasia diagnosis and treatment on self-esteem and body image. Gynecol Oncol 1989;34:345-349.
28 NHS Pocket Screening booklet
29 Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005;32S:S1-6.
30 Munoz N, Bosch FX, Castellsague X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-285.
31 Clifford GM, Smith JS, Plummer M et al. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003;88:63-73.
32 Clifford GM, Smith JS, Aguado T et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A meta-analysis. Br J Cancer 2003;89:101-105.
33 Clifford GM, Rana RK, Franceschi S et al. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-1164.
34 von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-604.
35 Collins S, Mazloomzadeh S, Winter H et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002;109:96-98.
36 Puig-Tintoré L.M., Cortés X., Castellsagué X., Torné A. et al. Prevención del Cáncer de cuello uterino, ante la vacunación frente al virus del Papiloma Humano. Prog. Obstetricia Ginecol. 2006; 49 supl. 2: 5-62
37 van Ballegooijen M, van den Akker-van Marle E, Patnick J et al. Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur J Cancer 2000;36:2177-2188.
38 Anttila A, Ronco G, Clifford G et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004;91:935-941.
39 Sawaya GF, McConnell KJ, Kulsingam SL et al. Risk of cervical cancer associated with extending the interval between cervical cancer screenings. N Engl J Med 2003;349:1501-1509.
40 Clinical Effectiveness Group (Association for Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). National guideline for the management of anogenital warts.
41 Madeleine MM, Daling JR, Carter JJ et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 1997;89:1516-1523.
42 Daling JR, Madeleine MM, Schwartz SM et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 2002;84:263-270.
43 Parkin DM, Whelan SL, Ferlay J et al. Cancer incidence in five continents (CIS). Volume VIII. P606-611
44 Dodge JA, Eltabbakh GH, Mount SL et al. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol 2001;83:363-369
45 Van Beurden M, ten Kate FJW, Smiths HL et al. Multifocal intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus. Cancer 1995;75:2879-2884
46 Hording U, Junge J, Poulson H et al. Vulvar intraepithelial neoplasia III: A viral disease if undetermined progressive potential. Gynecol Oncol 1995;56:276-279
47 Jones RW. Vulval intraepithelial neoplasia: Current perspectives. Eur J Gynaecol Oncol 2001;22:393-402
48 Esiashvili N, Landry J and Matthews RH. Carcinoma of the anus: Strategies in management. The Oncologist 2002;7:188-199.
49 Kosko JR and Derkay CS. Role of cesarean section in prevention of recurrent respiratory papillomatosis - Is there one? Int J Pediatr Otorhinolaryngol 1996;35:31-38.
50 Silverberg MJ, Thorsen P, Lindeberg H et al. Clinical course of recurrent respiratory papillomatosis in Danish children. Arch Otolaryngol Head Neck Surg 2004;130:711-716.
51 http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/sti-warts/epidemiology/epidemiology.htm#
52 McMillan A. The management of difficult anogenital warts. Sex Transm Inf 1999;75:192-194.
53 Quinn M, Babb P, Jones J et al. Effect of screening on incidence and mortality from cancer and cervix in England: Evaluation based on routinely collected statistics. BMJ 1999; 318: 904-908
54 Hybrid Capture 2 Package Insert, page 27 points 2 and 3a
55 Renshaw AA, DiNisco SA, Minter LJ et al. A more accurate measure of the false-negative rate of Papanicolaou smear screening is obtained by determining the false-negative rate of the rescreening process. Cancer Cytopathol 1997;81:272-276.
56 Kjaer SK, Chackerian B, van den Brule AJC et al. High-risk human papillomavirus is sexually transmitted: Evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001;10:101-106.
57 Maw RD, Reitano M and Roy M. An international survey of patients with genital warts: Perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571-578.

Glosario

Términos relacionados con el virus del papiloma humano y el cáncer de cuello de útero

Más info

Referencias

Más info

Testimoniales

Pilar 48 años

Aunque se hacía revisiones ginecológicas cada tres meses, tardaron un año en detectar el cáncer.

Más info